+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Distribution Channel, Therapy Type, End User - Global Forecast to 2030- Product Image
Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Distribution Channel, Therapy Type, End User - Global Forecast to 2030- Product Image
Sale

Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Distribution Channel, Therapy Type, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5264372
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antidiabetic Drugs Market grew from USD 51.42 billion in 2024 to USD 56.79 billion in 2025. It is expected to continue growing at a CAGR of 10.26%, reaching USD 92.41 billion by 2030.

Navigating the Evolution of Antidiabetic Treatment Options

The global landscape of antidiabetic therapeutics has evolved dramatically over recent decades, catalyzed by rising diabetes prevalence and breakthroughs in pharmacology. Novel analog insulins and targeted oral agents are redefining glycemic control, while digital health solutions and patient-centric delivery devices are enhancing adherence and outcomes. These advancements have ushered in a new era of personalized diabetes management, where therapy selection is informed by patient phenotype, comorbidities, and lifestyle factors rather than a one-size-fits-all paradigm.

In this dynamic context, industry stakeholders must navigate complex regulatory pathways, shifting reimbursement frameworks, and an increasingly competitive innovation pipeline. Simultaneously, payers and healthcare providers are demanding robust real-world evidence to justify therapy costs and demonstrate long-term value. The following executive summary synthesizes transformative market shifts, policy impacts, segmentation analyses, and actionable recommendations designed to empower strategic decision-making and sustain leadership in the antidiabetic drugs arena.

Pivotal Shifts Reshaping the Antidiabetic Therapeutics Arena

The antidiabetic drug sector is undergoing transformative realignments driven by scientific, regulatory, and commercial catalysts. Biotechnological advances have accelerated the development of novel modalities such as dual and triple agonists that target multiple metabolic pathways, promising superior glycemic and weight outcomes. Regulatory agencies are responding with expedited review mechanisms, encouraging early engagement and adaptive trial designs to balance safety with faster patient access.

Concurrently, digital therapeutics and connected devices are converging with pharmacotherapy to enable remote monitoring, predictive analytics, and individualized dosing algorithms. Strategic collaborations between pharmaceutical innovators and technology firms are creating integrated solutions that extend beyond biochemical control to encompass behavioral and lifestyle interventions. This convergence is altering competitive dynamics, compelling legacy manufacturers to adapt or partner to retain market share and address unmet patient needs.

Assessing the 2025 Tariff Effects on US Antidiabetic Imports

In 2025, the United States will implement revised tariff schedules on imported pharmaceutical inputs, affecting API sourcing and finished product imports. These adjustments introduce incremental cost pressures that vary across molecule classes. Insulin analogs, often reliant on specialized manufacturing equipment overseas, face steeper raw material levies, translating into potential price increases across distribution channels. Conversely, domestic production incentives for certain chemical entities may partially offset these impacts.

The cumulative effect of these tariffs requires strategic procurement realignment and may spur onshoring initiatives. Manufacturers with vertically integrated supply chains or established US-based biologics facilities will likely navigate the tariff landscape with greater resilience. Conversely, smaller players and contract manufacturers dependent on cross-border trade may encounter margin compression, prompting consolidation or renegotiation of supplier agreements to preserve competitive pricing structures.

Dissecting Market Variations Through Comprehensive Segmentation

A granular segmentation lens reveals divergent growth trajectories and adoption patterns across drug classes, patient cohorts, administration routes, distribution networks, therapy regimens, and end-user settings. When analyzed by drug class, the market splits into insulin and oral agents. Insulin further subdivides into analog insulin and human insulin, with analog insulin encompassing long-acting, rapid-acting, and ultra-long-acting variants. Oral agents include biguanides, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and sulfonylureas, each addressing different aspects of glycemic control.

Patient type segmentation distinguishes among gestational diabetes, prediabetes, type 1 diabetes, and type 2 diabetes, reflecting the spectrum of glycemic dysregulation and therapeutic complexity. Route of administration partitions into oral and parenteral options, signifying divergent adherence and delivery considerations. Distribution channels span hospital pharmacy, online pharmacy, and retail pharmacy, each with unique regulatory and reimbursement pathways. Therapy type dichotomizes between combination therapy and monotherapy, illustrating the shift toward multi-mechanistic regimens. Finally, end users include clinics, home care environments, and hospitals, underscoring the trend toward decentralized chronic disease management.

Regional Dynamics Driving Antidiabetic Drug Adoption Worldwide

Regional forces shape demand patterns and competitive landscapes in markedly different ways. In the Americas, the United States remains the epicenter of innovation and volume consumption, fueled by high diabetes prevalence and substantial R&D investment, while Latin American markets exhibit rapid growth driven by increasing healthcare spending and expanding insurance coverage.

Within Europe, Middle East & Africa, pricing negotiations and health technology assessments drive market access strategies, compelling manufacturers to demonstrate cost-effectiveness in national formulary submissions. Emerging markets in the Middle East and North Africa are experiencing capacity expansions in biologics production and specialized diabetes care clinics. Asia-Pacific presents a dual narrative, with mature markets like Japan adopting premium branded therapies alongside burgeoning demand in India and China, where generics and biosimilars play a critical role in addressing affordability challenges.

Profiling Industry Leaders and Their Strategic Movements

Leading pharmaceutical and biotechnology corporations are executing targeted strategies to secure market leadership. Global insulin pioneer entities have consolidated their portfolios through high-profile acquisitions and pipeline licensing, reinforcing their dominance in analog and biosimilar segments. Orally administered therapy frontrunners are diversifying into fixed-dose combination offerings and digital adherence platforms to enhance patient retention.

Mid-tier specialty players are carving niches with novel mechanisms of action and diabetic foot ulcer therapeutics, leveraging fast-to-market approvals in select regions. Contract development and manufacturing organizations are scaling biologics capabilities to meet growing biopharmaceutical demand, establishing strategic alliances with both originators and emerging innovators. Collectively, these corporate maneuvers underscore a landscape where agility, pipeline depth, and cross-sector collaboration define competitive advantage.

Strategic Imperatives for Stakeholders in Antidiabetic Therapies

Executives should prioritize strategic collaborations that integrate digital health technologies with pharmacotherapy to differentiate offerings and improve adherence outcomes. Investment in flexible manufacturing platforms will mitigate risks associated with tariff fluctuations and supply chain disruptions. Payers and providers are increasingly valuing real-world evidence; therefore, establishing robust data collection networks and outcome registries will support value-based contracting.

Geographic expansion efforts should align with regional reimbursement profiles and regulatory timelines, leveraging local partnerships to accelerate market entry. A clear roadmap for transitioning patients from monotherapy to multi-mechanistic regimens can capture incremental revenue while addressing treatment inertia. Finally, embedding patient education initiatives and support services within commercial strategies will strengthen brand loyalty and optimize long-term retention in chronic care pathways.

Robust Research Framework Upholding Data Integrity

This analysis employs a hybrid research methodology combining primary and secondary data sources. Expert interviews with endocrinologists, payers, and market access specialists provided qualitative insights into emerging clinical practice trends and policy developments. Publicly available regulatory filings, corporate financial disclosures, and patent databases were systematically reviewed to map competitive pipelines and investment flows.

Quantitative data was triangulated from government health statistics, proprietary treatment registries, and trade association reports to ensure robust cross-validation. Segmentation and regional analyses were designed using standardized frameworks to facilitate comparability. Rigorous quality checks, including consistency reviews and methodological audits, were conducted throughout the research lifecycle to uphold data integrity and support actionable conclusions.

Concluding Perspectives on Antidiabetic Market Trajectories

The antidiabetic drugs market stands at a critical inflection point, characterized by rapid innovation, evolving policy landscapes, and shifting patient expectations. Advanced therapies and integrated digital solutions are redefining the standard of care, while tariff realignments and reimbursement pressures demand adaptive commercial strategies. Segmentation insights reveal nuanced growth pockets and therapeutic preferences that can guide portfolio optimization and market prioritization.

Regional dynamics underscore the importance of tailored access approaches, balancing global standardization with local flexibility. Industry leaders are capitalizing on strategic alliances, manufacturing investments, and real-world evidence generation to fortify their market positions. As the market continues to converge on personalized, outcome-driven care models, stakeholders who act swiftly on these insights will be best positioned to drive sustainable growth and deliver meaningful improvements in patient health.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Insulin
      • Analog Insulin
        • Long-Acting
        • Rapid-Acting
        • Ultra-Long-Acting
      • Human Insulin
    • Oral Agents
      • Biguanides
      • DPP-4 Inhibitors
      • GLP-1 Receptor Agonists
      • SGLT-2 Inhibitors
      • Sulfonylureas
  • Patient Type
    • Gestational Diabetes
    • Prediabetes
    • Type 1 Diabetes
    • Type 2 Diabetes
  • Route Of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Therapy Type
    • Combination Therapy
    • Monotherapy
  • End User
    • Clinics
    • Home Care
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antidiabetic Drugs Market, by Drug Class
8.1. Introduction
8.2. Insulin
8.2.1. Analog Insulin
8.2.1.1. Long-Acting
8.2.1.2. Rapid-Acting
8.2.1.3. Ultra-Long-Acting
8.2.2. Human Insulin
8.3. Oral Agents
8.3.1. Biguanides
8.3.2. DPP-4 Inhibitors
8.3.3. GLP-1 Receptor Agonists
8.3.4. SGLT-2 Inhibitors
8.3.5. Sulfonylureas
9. Antidiabetic Drugs Market, by Patient Type
9.1. Introduction
9.2. Gestational Diabetes
9.3. Prediabetes
9.4. Type 1 Diabetes
9.5. Type 2 Diabetes
10. Antidiabetic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
11. Antidiabetic Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Antidiabetic Drugs Market, by Therapy Type
12.1. Introduction
12.2. Combination Therapy
12.3. Monotherapy
13. Antidiabetic Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
14. Americas Antidiabetic Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antidiabetic Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antidiabetic Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novo Nordisk A/S
17.3.2. Sanofi S.A.
17.3.3. Eli Lilly and Company
17.3.4. Merck & Co., Inc.
17.3.5. AstraZeneca plc
17.3.6. Boehringer Ingelheim International GmbH
17.3.7. Johnson & Johnson
17.3.8. Pfizer Inc.
17.3.9. Novartis AG
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIDIABETIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIDIABETIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 64. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 65. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 118. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 119. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 128. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 133. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 145. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 146. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 147. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 151. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 154. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 155. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 156. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 160. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 190. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 191. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 192. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 208. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 209. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 210. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 214. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 217. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 218. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 223. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 244. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 245. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 246. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 250. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 253. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 254. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 255. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 271. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 272. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 277. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 280. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 281. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 282. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 286. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 306. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 308. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 309. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 310. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 314. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 316. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 317. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 318. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 319. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 320. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 323. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 326. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 327. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 328. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 329. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF A

Companies Mentioned

The companies profiled in this Antidiabetic Drugs market report include:
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 56.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 92.41 Billion
Compound Annual Growth Rate10.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Antidiabetics Market Report 2025 - Product Image

Antidiabetics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Antidiabetics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Antidiabetics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From
Oral Antidiabetic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Oral Antidiabetic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 145 Pages
  • Global
From

About the Antidiabetic Market

The Antidiabetic market is a subset of Endocrine and Metabolic Disorders Drugs, which are used to treat a variety of conditions related to hormones and metabolism. Antidiabetic drugs are used to treat diabetes, a chronic condition in which the body does not produce or properly use insulin. These drugs can help control blood sugar levels, reduce the risk of complications, and improve quality of life. Common antidiabetic drugs include insulin, sulfonylureas, biguanides, thiazolidinediones, and meglitinides. Some companies in the Antidiabetic market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies produce a variety of antidiabetic drugs, including insulin, oral medications, and combination products. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.